Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution
This longitudinal study (n=57) investigated the effects of ayahuasca and found improved convergent thinking/creativity, decreased ratings of depression and stress up to four weeks later. These changes were significantly correlated with the level of ego dissolution experienced during the acute trip/ceremony.
Authors
- Jordi Riba
- Kim Kuypers
- Johannes Ramaekers
Published
Abstract
Rationale
Ayahuasca is a psychotropic plant tea from South America used for religious purposes by indigenous people of the Amazon. Increasing evidence indicates that ayahuasca may have therapeutic potential in the treatment of mental health disorders and can enhance mindfulness-related capacities. Most research so far has focused on acute and sub-acute effects of ayahuasca on mental health-related parameters and less on long-term effects.
Objectives
The present study aimed to assess sub-acute and long-term effects of ayahuasca on well-being and cognitive thinking style. The second objective was to assess whether sub-acute and long-term effects of ayahuasca depend on the degree of ego dissolution that was experienced after consumption of ayahuasca.
Results
Ayahuasca ceremony attendants (N = 57) in the Netherlands and Colombia were assessed before, the day after, and 4 weeks following the ritual. Relative to baseline, ratings of depression and stress significantly decreased after the ayahuasca ceremony and these changes persisted for 4 weeks. Likewise, convergent thinking improved post-ayahuasca ceremony up until the 4 weeks follow-up. Satisfaction with life and several aspects of mindfulness increased the day after the ceremony, but these changes failed to reach significance 4 weeks after. Changes in affect, satisfaction with life, and mindfulness were significantly correlated to the level of ego dissolution experienced during the ayahuasca ceremony and were unrelated to previous experience with ayahuasca.
Conclusion
It is concluded that ayahuasca produces sub-acute and long-term improvements in affect and cognitive thinking style in non-pathological users. These data highlight the therapeutic potential of ayahuasca in the treatment of mental health disorders, such as depression.
Research Summary of 'Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution'
Introduction
Ayahuasca is a traditional Amazonian plant brew that combines DMT-containing Psychotria viridis with MAO-inhibiting Banisteriopsis caapi alkaloids, producing prolonged psychedelic effects. Earlier work has reported acute increases in aspects of mindfulness and divergent thinking during the psychedelic state, anecdotal reports of spiritual insight and improved outlook, and preliminary clinical observations of rapid antidepressant effects lasting days to weeks. However, most research has concentrated on acute and sub-acute effects, and there is limited evidence on whether such effects persist over longer intervals or how they relate to aspects of the acute experience such as ego dissolution. Uthaug and colleagues set out to evaluate sub-acute (the day after) and longer-term (4 weeks) changes in affect, mindfulness-related capacities, and cognitive thinking style in naturalistic ceremony attendants. A secondary aim was to test whether these changes were associated with the intensity of ego-dissolution experienced during the ayahuasca ceremony. The researchers hypothesised increases in mindfulness, life satisfaction, and divergent thinking together with reductions in depression, anxiety, and stress, and expected that positive changes would correlate with ego-dissolution ratings and persist at 4 weeks.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Uthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018). Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology, 235(10), 2979-2989. https://doi.org/10.1007/s00213-018-4988-3
References (17)
Papers cited by this study that are also in Blossom
Bouso, J. C., González, D., Fondevila, S. et al. · PLOS ONE (2012)
da Silveira, D. X., Doering-Silveira, E., Grob, C. S. et al. · Journal of Psychoactive Drugs (2005)
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
Halpern, J. H., Sherwood, A. R., Passie, T. et al. · Medical Science Monitor (2008)
Idell, R. D., Florova, G., Komissarov, A. A. et al. · Medical Hypotheses (2017)
Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)
McKenna, D. · ACS Chemical Neuroscience (2004)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Show all 17 referencesShow fewer
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)
Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)
Trichter, S. · Journal of Transpersonal Psychology (2010)
Trichter, S., Klimo, J., Krippner, S. · Journal of Psychoactive Drugs (2009)
Viol, A., Palhano-Fontes, F., Onias, H. et al. · Scientific Reports (2017)
Cited By (66)
Papers in Blossom that reference this study
Bonomo, Y. A., Norman, A. F., Collins, L. et al. · Frontiers in Psychiatry (2025)
Reckweg, J. T., Mason, N. L., Theunissen, E. L. et al. · Frontiers in Psychology (2025)
Caspani, G., Ruffell, S. G. D., Tsang, WF. et al. · Pharmacological Research (2024)
Sloshower, J. A., Zeifman, R. J., Guss, J. et al. · Scientific Reports (2024)
Timmermann, C., Zeifman, R. J., Erritzoe, D. et al. · Scientific Reports (2024)
Solaja, I., Haldane, K., Mason, N. et al. · Neuroscience and Biobehavioral Reviews (2024)
Mason, N. L., Szabo, A., Kuypers, K. P. C. et al. · Brain Behavior and Immunity - Health (2023)
Buchborn, T., Kettner, H., Kartner, L. et al. · Frontiers in Neuroscience (2023)
Mallaroni, P., Mason, N. L., Kloft, L. et al. · Frontiers in Neuroscience (2023)
Ramaekers, J. G., Mallaroni, P., Kloft, L. et al. · Journal of Cognitive Neuroscience (2023)
Show all 66 papersShow fewer
Rossi, G. N., Rocha, J. M., Osório, F. L. et al. · Journal of Clinical Psychopharmacology (2023)
Azmoodeh, K., Thomas, E., Kamboj, S. K. · Experimental and Clinical Psychopharmacology (2023)
Newton, K., Moreton, S. G. · Ecopsychology (2023)
Simonsson, A., Simonsson, O., Chambers, R. et al. · Mindfulness (2023)
Aday, J. S., Skiles, Z., Eaton, N. et al. · Psychedelic Medicine (2023)
Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)
Perkins, D., Ruffell, S. G. D., day, K. et al. · Frontiers in Neuroscience (2023)
Bohn, A., Kiggen, M. H. H., Uthaug, M. V. et al. · International Journal for the Psychology of Religion (2022)
Simonsson, O., Hendricks, P. S., Chambers, R. et al. · Therapeutic Advances in Psychopharmacology (2022)
Bouso, J. C., Andión, O., Sarris, J. et al. · PLOS Global Public Health (2022)
Gattuso, J. J., Perkins, D., Ruffell, S. G. D. et al. · International Journal of Neuropsychopharmacology (2022)
Madsen, M. K., Ozenne, B., Armand, S. et al. · Frontiers in Psychology (2022)
Ornelas, I. M., Cini, F. A., Wießner, I. et al. · Experimental Neurology (2022)
Kałużna, A., Schlosser, M., Gulliksen Craste, E. et al. · Journal of Psychedelic Studies (2022)
Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)
Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)
Radakovic, C., Radakovic, R., Peryer, G. et al. · Journal of Psychedelic Studies (2022)
Costa, M. A. · Journal of Psychoactive Drugs (2022)
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)
Wießner, I., Olivieri, R., Falchi, M. et al. · European Neuropsychopharmacology (2022)
Orłowski, P., Ruban, A., Szczypiński, J. et al. · Journal of Psychopharmacology (2022)
Reckweg, J., Uthaug, M. V., Szabo, A. et al. · Journal of Neurochemistry (2022)
Wießner, I., Falchi, M., Maia, L. O. et al. · Journal of Psychopharmacology (2022)
Ramaekers, J. G. · Psychopharmacology (2022)
Simonsson, O., Goldberg, S. B. · Journal of Psychoactive Drugs (2022)
van Oorsouw, K., Uthaug, M. V., Mason, N. L. et al. · Journal of Psychedelic Studies (2021)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
Zamani, A., Carhart-Harris, R. L., Christoff, K. · Neuropsychopharmacology (2021)
Kuiperes, Z., Schreiber, R. · Neurobiology of Learning and Memory (2021)
Davis, A. K., Xin, Y., Sepeda, N. D. et al. · Chronic Stress (2021)
Hübner, S., Haijen, E. C. H. M., Kaelen, M. et al. · Journal of Medical Internet Research (2021)
Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)
Wießner, I., Falchi, M., Palhano-Fontes, F. et al. · Psychological Medicine (2021)
Ruffell, S. G. D., Netzband, N., Tsang, W. et al. · Frontiers in Psychiatry (2021)
Gearin, A. K., Devenot, N. · International Journal of Cultural Studies (2021)
Cox, D. J., Garcia-Romeu, A., Johnson, M. W. · The American Journal of Drug and Alcohol Abuse (2021)
Perkins, D., Schubert, V., Simonová, H. et al. · Frontiers in Pharmacology (2021)
Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)
Uthaug, M. V., Mason, N. L., Toennes, S. W. et al. · Psychopharmacology (2021)
Aday, J. S., Davis, A. K., Mitzkovitz, C. M. et al. · ACS Pharmacology and Translational Science (2021)
O'shaughnessy, D. M., Berlowitz, I., Rodd, R. et al. · Therapeutic Advances in Psychopharmacology (2021)
Galvão-Coelho, N. L., Marx, W., Sinclair, J. et al. · Psychopharmacology (2021)
Maia, L. O., Daldegan-Bueno, D., Tófoli, L.F. · Journal of Psychoactive Drugs (2020)
Aday, J. S., Davoli, C. C., Bloesch, E. K. · Therapeutic Advances in Psychopharmacology (2020)
Zeifman, R. J., Wagner, A. C., Watts, R. et al. · Frontiers in Psychiatry (2020)
Kangaslampi, S., Hausen, A., Rauteenmaa, T. · Journal of Psychoactive Drugs (2020)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Jiménez-Garrido, D. F., Gómez-Sousa, M., Ona, G. et al. · Scientific Reports (2020)
Nichols, C. D., Hendricks, P. S. · Handbook of Behavioral Neuroscience (2020)
Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)
Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2020)
Araújo, D. B., Zeifman, R. J., Palhano-Fontes, F. et al. · Frontiers in Pharmacology (2019)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Kuypers, K. P. C. · Medical Hypotheses (2019)
Mason, N. L., Mischler, E., Uthaug, M. V. et al. · Journal of Psychoactive Drugs (2019)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.